Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

NCT02632708 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

153

Enrollment

OTHER

Sponsor class

Conditions

Newly Diagnosed Acute Myeloid Leukemia (AML)
Untreated AML
AML Arising From Myelodysplastic Syndrome (MDS)
AML Arising From Antecedent Hematologic Disorder (AHD)
AML Arising After Exposure to Genotoxic Injury

Interventions

DRUG: AG-120
DRUG: AG-221
DRUG: cytarabine
DRUG: daunorubicin
DRUG: idarubicin
DRUG: mitoxantrone
DRUG: etoposide

Sponsor

Institut de Recherches Internationales Servier

Collaborators

[object Object]